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Abstract
 
Susceptibility to multiple sclerosis (MS) is associated with the human histocompatibility leuko-
cyte antigen (HLA)-DR2 haplotype, suggesting that major histocompatibility complex class II–
restricted presentation of central nervous system–derived antigens is important in the disease
process. Antibodies specific for defined HLA-DR2–peptide complexes may therefore be valu-
able tools for studying antigen presentation in MS. We have used phage display technology to
select HLA-DR2–peptide-specific antibodies from HLA-DR2–transgenic mice immunized
with HLA-DR2 molecules complexed with an immunodominant myelin basic protein (MBP)
peptide (residues 85–99). Detailed characterization of one clone (MK16) demonstrated that
both DR2 and the MBP peptide were required for recognition. Furthermore, MK16 labeled
intra- and extracellular HLA-DR2–MBP peptide complexes when antigen-presenting cells
(APCs) were pulsed with recombinant MBP. In addition, MK16 inhibited interleukin 2 secre-
tion by two transfectants that expressed human MBP–specific T cell receptors. Analysis of the
structural requirement for MK16 binding demonstrated that the two major HLA-DR2 anchor
residues of MBP 85–99 and the COOH-terminal part of the peptide, in particular residues Val-
96, Pro-98, and Arg-99, were important for binding. Based on these results, the antibody was
used to determine if the HLA-DR2–MBP peptide complex is presented in MS lesions. The
antibody stained APCs in MS lesions, in particular microglia/macrophages but also in some
cases hypertrophic astrocytes. Staining of APCs was only observed in MS cases with the HLA-
DR2 haplotype but not in cases that carried other haplotypes. These results demonstrate that
HLA-DR2 molecules in MS lesions present a myelin-derived self-peptide and suggest that mi-
croglia/macrophages rather than astrocytes are the predominant APCs in these lesions.
Key words: multiple sclerosis • antigen presentation • myelin basic protein • autoimmunity • 
microglia
 
Introduction
 
Multiple sclerosis (MS)
 
1
 
 is a chronic inflammatory demyeli-
nating disease of the central nervous system (CNS) with
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unknown etiology. Inherited susceptibility to MS is as-
sociated with the HLA class II genes DRB1
 
*
 
1501,
DRB5
 
*
 
0101, and DQB1
 
*
 
0602, which are all contained in
the DR2 haplotype (1). Because these three genes are in
strong linkage disequilibrium, it has not been possible to
determine which of them are the principal MS risk genes.
Any of these three genes or combinations of them could
mediate the MHC class II–associated susceptibility to MS.
The exact role for the disease-associated MHC class II mol-
ecules in the pathogenesis of MS is not clear. One prevail-
ing hypothesis is that they present self-antigens to auto-
aggressive T cells that enter the CNS and induce an
inflammatory response that leads to clinical manifest disease
(2, 3).
The target autoantigens are unknown in MS, but, largely
based on their encephalitogenicity in animal models for this
disease, myelin basic protein (MBP), proteolipid protein
(PLP), and myelin oligodendrocyte glycoprotein are the
major candidates (for review see references 3 and 4). Inves-
tigations of the immune response against CNS-derived
proteins in MS patients have largely focused on MBP as a
candidate antigen. The MBP 84–103 peptide has been de-
fined as the strongest binder of all MBP peptides to the dis-
ease-associated HLA-DR2 molecules and is recognized by
T cell clones from patients and normal individuals with the
HLA-DR2 haplotype (5–7). Several lines of evidence indi-
cate, however, that T cells recognizing this epitope are
only in vivo activated in MS patients (6, 8–10). The mini-
mal epitope for HLA-DR2–restricted T cell recognition
has been mapped to residues 85–99 of MBP (7). T cell lines
against other regions of MBP have also been generated, al-
though less frequently (5, 6, 11–15).
The identity of the cells in the CNS that present myelin-
derived autoantigens to CD4
 
1
 
 T cells is not clear. Pheno-
typic and functional analyses have implicated both micro-
glia/macrophages and astrocytes (for review see references
16–18). To directly examine MHC class II–restricted pre-
sentation of a myelin antigen in MS lesions, we have gen-
erated an mAb (MK16) that is specific for the HLA-DR2
(DRB1
 
*
 
1501)-bound MBP 85–99 peptide. Here we de-
scribe the generation and a detailed characterization of this
antibody and demonstrate how it can be used to detect
HLA-DR2–MBP 85–99 peptide complexes intra- and ex-
tracellularly when APCs have been incubated with native
MBP. This antibody was also used to examine antigen pre-
sentation in MS lesions and normal brain tissue. The anti-
body specifically labeled microglia/macrophages and in
some cases hypertrophic astrocytes from patients with the
HLA-DR2 haplotype, whereas these cells were not stained
in lesions from HLA-DR2–negative patients.
 
Materials and Methods
 
Cell Lines. Drosophila  melanogaster
 
 Schneider 2 (S2) cell
transfectants expressing either DRA1
 
*
 
0101/DRB1
 
*
 
1501
(DRB1
 
*
 
1501) or DRA1
 
*
 
0101/DRB1
 
*
 
0401 (DRB1
 
*
 
0401) mol-
ecules were grown at 25
 
8
 
C in Schneider’s medium (Sigma
Chemical Co.) supplemented with 10% heat-inactivated FCS, 2
 
mM 
 
l
 
-glutamine, 100 U/ml penicillin, and 100 
 
m
 
g/ml strepto-
mycin. The following transfectants and T cell hybridomas were
all grown at 37
 
8
 
C in DMEM (Sigma Chemical Co.) supple-
mented with 10% heat-inactivated FCS, 2 mM 
 
l
 
-glutamine, 100
U/ml penicillin, 100 
 
m
 
g/ml streptomycin, 50 
 
m
 
M 
 
b
 
-ME, and
1% nonessential amino acids: L cell transfectants expressing either
DRA1
 
*
 
0101/DRB5
 
*
 
0101 (DRB5
 
*
 
0101) or DRB1
 
*
 
1501 mole-
cules, the mouse BW 58 TCR-
 
a
 
/
 
b
 
 T cell hybridoma (19), and
four T cell transfectants expressing DRB1
 
*
 
1501-restricted hu-
man/mouse chimeric 
 
a
 
/
 
b
 
 TCR. Two of these T cell transfec-
tants recognize a human MBP–derived peptide corresponding to
residues 85–99 (Hy.2E11 and Ob.1A12; reference 20 and our
unpublished data), and the remaining two transfectants recognize
PLP-derived sequences corresponding to residues 40–60 (5C6)
and 95–116 (106J), respectively (our unpublished data).
The following EBV-transformed human B cell lines and
mouse T cell hybridomas were all grown at 37
 
8
 
C in RPMI
(Sigma Chemical Co.) supplemented with 10% heat-inactivated
FCS, 2 mM 
 
l
 
-glutamine, 100 U/ml penicillin, 100 
 
m
 
g/ml strep-
tomycin, and 50 
 
m
 
M 
 
b
 
-ME: Vavy expressing DR3 molecules
(DRA1
 
*
 
0101/DRB1
 
*
 
0301), Priess expressing DRB1
 
*
 
0401 mol-
ecules, and MGAR expressing DR2 molecules (DRB5
 
*
 
0101
and DRB1
 
*
 
1501); and two T cell hybridomas expressing
DRB1
 
*
 
0401-restricted mouse 
 
a
 
/
 
b
 
 TCR recognizing either a
human type II collagen–derived epitope corresponding to resi-
dues 261–273 (CII 261–273; hybridoma CII 3838) or an influ-
enza A hemagglutinin (HA)–derived epitope corresponding to
residues 307–319 (HA 307–319; hybridoma HA 3.3) (21).
 
Antigens.
 
Recombinant human MBP was expressed in 
 
Esch-
erichia coli
 
 using a cDNA construct with a COOH-terminal
(His)
 
6
 
-tag cloned into vector pET22b (Novagen). Expression
was induced by addition of isopropyl-
 
b
 
-
 
d
 
-thiolactopyranoside
(IPTG; 1 mM) to the growth media. The protein was purified
from lysed bacteria by metal-chelate chromatography, followed
by further purification using cation exchange HPLC (POROS
CM column; Perseptive Biosystems). The purified protein was
dialyzed against 0.01 N HCl and concentrated by vacuum di-
alysis.
Peptides were synthesized by Fmoc chemistry (Schafer-N,
Denmark; Microchemistry Facility, Harvard University); purity
(
 
.
 
95%) was verified by reverse-phase HPLC, and integrity was
verified by mass spectrometry. The following peptides were syn-
thesized: MBP 85–99 (ENPVVHFFKNIVTPR) and monosub-
stituted and -truncated analogues derived from this sequence; an
HLA-DQw6 peptide corresponding to residues 43–58 (DQw6
43–58) (DVGVYRAVTPQGRPDA); CII 261–273 (AG-
FKGEQGPKGEP); HA 307–319 (PKYVKQNTLKLAT); an in-
fluenza A HA peptide corresponding to residues 161–175 (HA
161–175) (YRNLVWFIKKNTRYP); a human Ig 
 
k
 
 peptide cor-
responding to residues 145–159 (SK 145–159) (KVQWKVD-
NALQSGNS); and two human PLP peptides, PLP 40–60
(TGTEKLIETYFSKNYQDYEYL) and PLP 95–116 (AVRQIF-
GDYKTTICGKGLSATV).
 
Transfection, Purification, and Functional Analysis of DR Molecules
from S2 Cells.
 
S2/DRB1
 
*
 
1501 and S2/DRB1
 
*
 
0401 molecules
were produced as previously described (22). In brief, cDNA en-
coding DRA1
 
*
 
0101, DRB1
 
*
 
1501, and DRB1
 
*
 
0401 was sepa-
rately cloned into the expression vector, pmtal, and pairwise
cotransfected with a third vector, pcohygro (encoding hygromy-
cin B resistance), into S2 cells using lipofection according to the
manufacturer’s instructions (GIBCO BRL). S2 cells expressing
the transfected constructs were selected and single-cell cloned.
After CuSO
 
4
 
 induction, detergent-solubilized HLA class II mole- 
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cules were purified using affinity chromatography. The purified
protein was characterized by SDS-PAGE followed by silver stain-
ing. The total protein concentration was determined by bicin-
choninic acid assay (Sigma Chemical Co.) using BSA as the refer-
ence protein. Peptide binding and inhibition assays with the
purified S2/DRB1
 
*
 
1501 and S2/DRB1
 
*
 
0401 molecules were
performed essentially as described in detail elsewhere (21, 22).
 
Generation and Purification of HLA–Peptide Complexes.
 
A vari-
ety of different HLA class II–peptide complexes were generated
by incubating detergent-solubilized and affinity-purified DRB1
 
*
 
1501 or DRB1
 
*
 
0401 molecules with 50–100
 
3
 
 molar excess of
different peptides at 25
 
8
 
C for 48–72 h in the presence of a pro-
tease inhibitor mixture (Complete; Boehringer Mannheim) and
0.1 M sodium citrate phosphate buffer, pH 6.0. After incubation,
the HLA–peptide complexes were subjected to a buffer exchange
and separated from free peptide by gel filtration on Sephadex
G-25 spin columns containing 0.1% NP-40 in PBS as previously
described (22).
 
Analysis of Antibody and Fab Specificity by ELISA.
 
HLA–pep-
tide specificity of serum from mice immunized with DRB1
 
*
 
1501–peptide complexes and the resulting antigen binding frag-
ment (Fab)-phages or purified Fab molecules were analyzed by
ELISA. Purified HLA–peptide complexes were diluted in PBS to
a final concentration of 0.1 
 
m
 
g/ml and coated onto 96-well mi-
crotiter plates (Maxisorp; Nunc, Inc.) followed by blocking with
2% skim milk in PBS. All washes between incubations were
performed with 0.05% Tween-20 in PBS. Serum, Fab-phages,
or purified Fab molecules were diluted in blocking buffer, added
to the microtiter wells, and incubated for 2 h at room tempera-
ture. Plates were washed, incubated with biotin-labeled second-
ary antibodies for 1 h at 4
 
8
 
C, washed again, and incubated for an
additional 1 h at room temperature with Eu
 
3
 
1
 
-labeled streptavi-
din (Wallac) in assay buffer (Wallac). Europium was released
by adding 100 
 
m
 
l per well of enhancement solution (Wallac),
and fluorescence was measured in a time-resolved fluorometer
(Wallac).
To determine the fine specificity of MK16, varying concentra-
tions of DRB1
 
*
 
1501 molecules incubated with monosubstituted
or truncated MBP peptide analogues were added as competitors
before the addition of MK16 Fab-phages to microtiter wells
coated with DRB1
 
*
 
1501–MBP 85–99 peptide complexes. The
concentration of HLA–peptide complex that prevented 50% of
the Fab-phages from binding to DRB1
 
*
 
1501–MBP 85–99 pep-
tide complexes was the IC
 
50
 
 (50% inhibiting dose) value. In a
preliminary experiment, the Fab-phages were titrated against a
fixed amount of DRB1
 
*
 
1501–MBP 85–99 peptide complex to
determine the concentration of Fab-phages corresponding to 10–
20% of the maximal response. All competition assays were per-
formed using these Fab-phage concentrations.
 
Immunization and Fab Phage Library Construction.
 
We used a
previously described method for displaying antibody (Fab frag-
ments) libraries on phages (23, 24). In brief, by using PCR-based
technology, Fab encoding genes derived from IgG cDNA from
immunized mice are amplified and assembled into a bicistronic
operon, which is inserted into a phagemid vector under transcrip-
tional control and transformed into 
 
E
 
. 
 
coli
 
. By using this cloning
strategy, libraries containing 
 
.
 
10
 
8
 
 potentially different clones can
be generated. After superinfection with a helper phage, the in-
fected bacteria produces recombinant phage particles, where each
phage represents a unique antibody encoded by genes present
within the same phage particle. The displayed antibodies on
phage particles allow for purification of antigen-specific phages
by repeated rounds of selection (panning) on a selected target fol-
 
lowed by amplification in bacterial cells of the eluted bound
phages.
Transgenic mice expressing DRB1
 
*
 
1501 molecules on a
DBA1/J background (20) and BALB/c mice (State Serum Insti-
tute, Denmark) were immunized with DRB1
 
*
 
1501–MBP 85–99
peptide complexes as previously described (24). Sera were har-
vested from immunized mice and tested for the presence of
DRB1
 
*
 
1501–MBP 85–99 peptide–specific antibodies by ELISA.
Mice producing such specificities were used to generate phage
display libraries of antibody Fab-fragments.
The Fab encoding genes were PCR amplified from cDNA
and assembled using a comprehensive sets of primers correspond-
ing to the Fab region of the heavy Fd and L 
 
k
 
 chains. The result-
ing Fab fragments were digested with SfiI and NotI, purified
from agarose gels, and ligated into a phagemid vector, pFab
5c.His, digested with the same enzymes to generate V
 
H
 
 and Fd
phagemid libraries (23). The resulting phagemid libraries were
transformed into electrocompetent 
 
E
 
.
 
 coli
 
 TOP10F
 
9
 
 cells (British
Biotechnology), and transformed cells were propagated in LB
(Luria-Bertani) medium containing 1% glucose, 100 
 
m
 
g/ml
ampicillin, and 20 
 
m
 
g/ml tetracycline. Phage libraries displaying
Fab fragments were generated by superinfection of exponentially
growing phagemid libraries with helper phage (R408; Stratagene
Inc.) followed by induction with 1 mM IPTG and amplified by
an overnight incubation at room temperature. The resulting Fab
phages were purified by polyethylene glycol precipitation and ti-
trated with 
 
E
 
.
 
 coli
 
 TOP10F9 cells (23).
Selection by Biopanning. Panning selections were performed
using 1.5 3 107 sulfate latex beads (diameter 5 mm; Interfacial
Dynamics) coated with a 0.5 mM solution of purified
DRB1*1501–MBP 85–99 peptide complexes. After blocking
with 5% BSA in PBS, 300 ml phage library containing 1011–1012
CFU in 5% BSA, 0.1% NP-40 in PBS was added to the coated
beads and incubated for 4 h at 48C with end-over-end rotation
followed by three to five washes with 5% BSA in PBS. After the
first round of panning, the subsequent rounds of panning were
performed in the presence of DRB1*1501 molecules at a con-
centration of 1 mM. Bound phages were eluted and used to infect
exponentially growing E. coli TOP10F9 cells, followed by super-
infection with helper phage (R408; Stratagene Inc.) and induc-
tion with IPTG and then overnight incubation and phage precip-
itation before initiating a new panning round (23, 24).
Expression and Purification of Soluble MK16 Fab Molecules. The
Fd (H chain of the Fab fragment) and k L chain encoding regions
were recloned by PCR into the T7 polymerase–driven expres-
sion vector pYR. Inclusion bodies of Fd and L chain were puri-
fied, solubilized, and refolded in a redox-shuffle buffer. Correctly
folded Fab molecules were purified by ion exchange (Q- and SP-
Sepharose) and size exclusion chromatography as previously de-
scribed (25).
FACS® Analysis. For flow cytometry analysis, z105 cells
were incubated with primary antibody for 1 h at 48C in FACS
buffer (PBS containing 5% FCS and 0.1% NaN3). After two
washes with FACS buffer, secondary biotin-labeled antibodies
were added for 1 h at 48C, and the cells were washed again and
incubated for 1 h at 48C with R-PE–labeled streptavidin (Becton
Dickinson). To quantitate DR expression, cells were incubated
directly with a biotin-labeled anti–HLA-DR mAb (mAb L243;
Becton Dickinson), followed by incubation with R-PE–labeled
streptavidin as described above. Cells were analyzed on a FAC-
Scan™ flow cytometer using CELLQuest™ software (Becton
Dickinson). A total of 10,000 cells per sample were analyzed, and
the viable cells were gated by light scatter.1398 Visualization of MBP T Cell Epitopes in MS Lesions
Preparation and Isolation of Adherent Mononuclear Cells from
Blood. 50 ml of peripheral blood was obtained from a DR2-
positive (DRB1*1501 homozygous) donor. PBMCs were imme-
diately separated by density gradient centrifugation on Ficoll
(Lymphoprep; Nycomed), washed three times, and resuspended
in tissue culture medium consisting of RPMI (Sigma Chemical
Co.) supplemented with 10% heat-inactivated FCS, 2 mM l-glu-
tamine, 100 U/ml penicillin, 100 mg/ml streptomycin, and 50
mM  b-ME, counted, and adjusted to 106 cells/ml. Next, the
mononuclear cells were incubated in culture flasks for 2 h at
378C and, after removal of the supernatant, the remaining adher-
ent cells were isolated, washed twice with culture medium, and
incubated with peptides for 2 h at 378C followed by FACS® anal-
ysis.
T Cell Stimulation Assay. Using round-bottomed microtiter
plates, 2 3 104 T cell hybridomas were cocultured in the pres-
ence of irradiated APCs (5 3 104 per well; MGAR and L cell
transfectants expressing DRB1*1501 and Priess expressing
DRB1*0401 molecules) and dilutions of recombinant MBP or
various peptides. After incubation for 24 h at 378C, 100 ml of the
supernatant was tested for IL-2 in an IL-2–specific sandwich
ELISA using Eu31-labeled streptavidin as detection system, as
previously described (21).
In separate experiments, purified DRB1*1501–peptide com-
plexes were coated directly to microtiter wells in serial dilutions
and used to stimulate T cell hybridomas. Microtiter wells were
blocked by 5% FCS in PBS and washed with 0.05% Tween-20 in
PBS before incubation with 2 3 104 T cell hybridomas at 378C
for 24 h. T cell stimulation was determined by using the IL-2
ELISA as described above.
Analysis by Confocal Laser Scanning Microscopy. L cells express-
ing DRB1*1501 were seeded onto Chamber Slides (Nalge Nunc
International) and grown at 378C overnight and then cultured
with or without peptides or recombinant MBP at 378C for 2 or
4 h. Cells were washed twice with culture medium and twice in
PBS, followed by fixation with 0.5% paraformaldehyde in PBS
for 20 min. After another wash with PBS, the cells were perme-
abilized with 0.2% saponin (Sigma Chemical Co.) for 30 min at
room temperature. Cells were blocked with PBS containing 2%
BSA and 0.2% saponin (blocking solution) for 30 min at room
temperature, washed, and simultaneously incubated with MK16
Fab and rat anti–mouse CD107a antibody (lysosome-associated
membrane protein [LAMP]-1; (PharMingen) diluted in blocking
solution overnight at 48C. The cells were washed four times with
blocking solution and incubated with FITC-labeled goat anti–
mouse IgG (Fab specific) absorbed against rat serum proteins
(Sigma Chemical Co.) and Texas Red–labeled F(ab9)2 fragment
goat anti–rat IgG antibodies (Fc fragment specific; Jackson Im-
munoResearch Labs.) diluted in blocking solution for 1 h at
room temperature. After three washes in PBS, chamber slides
bearing cells were mounted in Slowfade™ (Molecular Probes,
Inc.) antifade reagent in 50% glycerol, and staining of cells was
evaluated using an MCR-1024 confocal laser scanning micro-
scope (Bio-Rad Labs.) attached to a Zeiss Anxyovert 100 TV.
Green fluorescence was detected at wavelength 520–560 nm after
excitation at wavelength 488 nm. Red fluorescence was detected
at wavelength 585 nm after excitation at wavelength 568 nm.
Immunocytochemistry. Frozen sections were fixed in acetone
for 10 min and stained using either the avidin-biotin-peroxidase
technique (ABC; Vector Labs.) or double immunofluorescence.
Overnight incubations at 48C were performed with the following
mAbs: MK16, pan-reactive anti–HLA class II antibody to HLA-
DP-DQ-DR, anti-CD14 (microglia of the monocyte lineage,
monocytes and macrophages; DAKO Corp.), CD3 (pan T cells;
Becton Dickinson), and anti–glial fibrillary acidic protein (GFAP)
(astrocytes; Roche Molecular Biochemicals). The chromogen
used was 3,3-diaminobenzidine for bright field microscopy and,
for immunofluorescence, secondary mouse antibodies labeled
with Alexa 568, which is an anti–mouse IgG antibody (Molecular
Probes, Inc.), and Cy-2, which is an anti–mouse Fab fragment
(Jackson ImmunoResearch Labs.). Slides were scored in a blinded
fashion by two observers on a scale of 0–4 based on the degree of
positivity.
Results
The goal of this study was to generate mAbs specific for
the complex of HLA-DR2 (DRB1*1501) and the immu-
nodominant human MBP 85–99 peptide. Such antibodies
are difficult to generate, as many antibodies elicited by im-
munization are directed against the HLA molecule and do
not require a specific peptide for recognition. We therefore
immunized HLA-DR2 (DRA1*0101, DRB1*1501) trans-
genic mice, because tolerance to the HLA-DR2 molecule
might favor the production of antibodies specific for the
HLA-DR2–MBP peptide complex. To efficiently select
for potentially rare clones, antibodies were isolated by
phage display technology rather than conventional hybrid-
oma technology.
Purification and Functional Characterization of Purified
DRB1*1501 Molecules. It was important to efficiently
load DRB1*1501 molecules with the MBP 85–99 peptide
for immunization of DRB1*1501 transgenic mice. As HLA
class II molecules that are occupied by low-affinity endoge-
nous peptides or devoid of peptides can be produced in
insect cells (for example, see references 22 and 26),
DRB1*1501 molecules were expressed in S2 cells using full
length DRA1*0101 and DRB1*1501 cDNAs. Detergent-
solubilized DRB1*1501 molecules from these cells were
purified by affinity chromatography and characterized by
SDS-PAGE as well as by peptide binding and T cell stimu-
lation assays (data not shown). SDS-PAGE analysis resolved
the individual DRa and DRb chains when the sample was
heated and the heterodimer of z52 kD when the sample
was not heated before loading. Specific and dose-depen-
dent inhibition of peptide binding was observed with the
MBP 85–99, DQw6 43–58, PLP 40–60, and PLP 95–116
peptides, which are known to bind DRB1*1501 molecules
(7, 15, 27, 28), whereas no inhibition was seen with SK
145–159, which binds to DRB1*0401 molecules (data not
shown). MBP 85–99 peptide bound DRB1*1501 mole-
cules with an IC50 of 5 nM; the IC50 values for the DQw6
43–58, PLP 40–60, and PLP 95–116 peptides were 70,
200, and 1,480 nM, respectively. DRB1*1501–MBP pep-
tide complexes, but not other DRB1*1501–peptide com-
plexes, stimulated IL-2 production by a DRB1*1501-
restricted T cell hybridoma specific for the MBP peptide.
Likewise, only DRB1*1501–PLP 40–60 and DRB1*1501–
PLP 95–116 complexes, respectively, stimulated the two
PLP-specific T cell hybridomas (data not shown). Taken
together, these data demonstrated that the purified1399 Krogsgaard et al.
DRB1*1501 molecules were functional with respect to
binding of selected peptides and subsequent T cell stimula-
tion.
Immunization Strategy. Transgenic mice expressing HLA-
DRA*0101/DRB1*1501-encoded molecules on a DBA1/J
background (H-2q) and nontransgenic BALB/c (H-2d)
mice were Bacillus Calmette-Guerin (BCG) primed and
immunized with purified DRB1*1501–MBP 85–99 pep-
tide complexes coupled to tuberculin purified protein de-
rivative. This immunization scheme has been successfully
used to generate MHC–peptide-specific antibodies (24,
29). The syngenic immunization strategy was chosen to fa-
cilitate the generation of antibodies that specifically recog-
nize the DRB1*1501–MBP 85–99 peptide complex, rather
than pan-reactive anti-DR antibodies. Nontransgenic
BALB/c mice were also immunized to directly address this
issue. Four mice of each type were immunized, and two of
four syngenic immunizations, but none of the allogenic
immunizations, elicited an antibody response to the
DRB1*1501–MBP 85–99 peptide complex that could be
detected in the serum and distinguished from the pan-reac-
tive anti-DR response. In one of these mice (DRB1*1501-
1), the serum exhibited a 50-fold higher reactivity with
DRB1*1501–MBP 85–99 peptide complexes than with
“empty” DRB1*1501 molecules or DRB1*1501 with a
control peptide (Fig. 1), whereas this difference was five-
fold in the other mouse (DRB1*1501-2; data not shown).
Spleens from such mice were used to generate phage librar-
ies displaying Fab molecules on phage particles.
Construction of Phage Display Library and Panning Approach.
The resulting Fab-phage library consisted of 1.7 3 108 in-
dependent clones and was panned on immobilized DRB1*
1501–MBP 85–99 peptide complexes. Soluble, empty
DRB1*1501 molecules were added as competitors to neu-
tralize pan-specific anti-DR antibodies that might also have
been elicited. Fab-phages isolated after each round of pan-
ning were analyzed for binding to DRB1*1501–MBP 85–
99 peptide complexes, DRB1*1501–DQw6 43–58 peptide
complexes, or empty DRB1*1501 molecules by ELISA. As
illustrated in Fig. 2, Fab-phages recognizing DRB1*1501–
MBP 85–99 peptide complexes were successively enriched
during panning rounds 1 to 5, whereas pan-reactive DRB1*
1501 Fab-phages were effectively removed during rounds 4
and 5. Fab-phages produced from randomly picked clones
isolated after the fourth and fifth rounds of panning were
analyzed by ELISA, and 79 of 175 (45%) Fab-producing
clones reacted strongly with DRB1*1501–MBP 85–99
peptide complexes but not with DRB1*1501–DQw6 43–58
peptide complexes or empty DRB1*1501 molecules. 61
clones (35%) had the same specificity but reacted more
weakly. 9 clones (5%) were not specific for the DRB1*1501–
MBP peptide complex but also reacted with DRB1*1501–
DQw6 43–58 complexes and with empty DRB1*1501
molecules. The remaining 26 clones (15%) did not bind to
DRB1*1501 molecules in complex with MBP 85–99,
DQw6 43–58 peptides, or empty DRB1*1501 molecules.
Restriction fragment length polymorphism analysis
showed that the clones that were specific for the
DRB1*1501–MBP 85–99 peptide complex could be di-
vided into 10 different groups. One clone from each group
was reanalyzed by ELISA for reactivity to DRB1*1501–
MBP 85–99 peptide complexes, DRB1*1501–DQw6 43–
58 peptide complexes, and empty DRB1*1501 molecules,
as well as DRB1*0401 molecules in complex with HA
307–319 or CII 261–273 peptides. All 10 clones reacted
Figure 1. Immunizations of transgenic mice with purified
DRB1*1501–MBP 85–99 peptide complexes elicit antibodies specific for
the HLA-DRB1*1501–MBP peptide complex. After three immuniza-
tions, sera from (A) transgenic mice or (B) BALB/c mice were analyzed
by ELISA for the presence of antibodies against the DRB1*1501–MBP
peptide complex. Microtiter wells were coated with purified
DRB1*1501–MBP 85–99, DRB1*1501–DQw6 43–58, or DRB1*0401–
HA 307–319 complexes or without complexes. Bound antibodies were
detected with biotin-labeled rabbit anti–mouse Igs. Each symbol repre-
sents a single determination. (C) The amount of DR–peptide complex
immobilized was quantitated with biotin-labeled mAb L243. The mean
and SEM (n 5 2) are shown.1400 Visualization of MBP T Cell Epitopes in MS Lesions
only with the DRB1*1501–MBP 85–99 peptide com-
plexes (data not shown). These 10 clones were next ana-
lyzed in a FACS® assay, and five of the clones, which rep-
resented five different groups, reacted significantly better
with MGAR cells (expressing DRB5*0101 and DRB1*
1501 molecules) incubated with MBP 85–99 peptide than
with MGAR cells incubated with a control peptide or no
peptide. The other five clones did not make this distinction
(data not shown).
The DNA sequences of the H and L chain CDRs of the
five clones that were specific for the DRB1*1501–MBP
85–99 peptide complex were determined. The CDR-H3
regions were identical, but minor amino acid differences
were present in the other CDR regions (data not shown).
The IC50 values of the individual clones were determined
by ELISA, and no significant differences in affinity were ob-
served (data not shown). These data demonstrated that these
phages represented individual clones and that a strong selec-
tion for a particular H chain rearrangement had occurred.
Specificity of Purified MK16. Soluble Fab molecules
were produced from one DRB1*1501–MBP 85–99-spe-
cific clone (MK16), because it showed the highest reactiv-
ity by FACS® analysis (data not shown). In a competition
assay, binding of MK16 to immobilized DRB1*1501–
MBP 85–99 peptide complexes was inhibited in a specific
and dose-dependent manner by soluble DRB1*1501–MBP
85–99 peptide complexes (Fig. 3), but neither component
could inhibit alone, nor could irrelevant DRB1*1501–
DQw6 43–58 complexes.
It was important to demonstrate that the antibody also
recognized DRB1*1501–MBP 85–99 peptide complexes
expressed by mammalian cells. Significant staining with
MK16 was seen when L cells expressing DRB1*1501 (Fig.
4 A) and adherent mononuclear cells from a DRB1*1501-
positive donor had been cultured with MBP 85–99 peptide
(Fig. 5), but not when these cells had been incubated with
DQw6 43–58 peptide or media only. No significant stain-
ing was seen with L cells that expressed DRB5*0101 mole-
cules and had been incubated with MBP 85–99 peptide,
DQw6 43–58 peptide, or no peptide (Fig. 4 B).
It was also important to determine if MK16 could recog-
nize DRB1*1501–MBP peptide complexes produced by
intracellular processing of native MBP. MK16 stained
MGAR cells incubated with recombinant MBP almost at
the same level of intensity as MGAR cells incubated with
MBP 85–99 peptide (Fig. 6). No specific staining was seen
with MGAR cells that presented endogenous peptides or
DQw6 43–58. We also examined EBV-transformed hu-
man B cell lines that express DRB1*0301 molecules (B cell
line Vavy) or DRB1*0401 molecules (B cell line Priess)
and that had been cultured in the presence of recombinant
MBP, MBP 85–99, or DQw6 43–58 peptides. No specific
staining was observed, indicating that the antibody was spe-
cific for the DRB1*1501–MBP peptide complex (data not
shown). These results demonstrated that recognition by
MK16 was dependent on the simultaneous presence of
DRB1*1501 and MBP 85–99 peptide and that MK16
could detect DRB1*1501–MBP 85–99 peptide complexes
independent of whether they were formed from synthetic
MBP 85–99 peptide or processed recombinant MBP.
Figure 3. Binding characteristics of MK16 by competition ELISA. Mi-
crotiter wells coated with DRB1*1501–MBP 85–99 peptide complexes
were incubated with a fixed amount of MK16 Fab-phages and various
concentrations of soluble DRB1*1501–MBP 85–99 peptide complexes,
DRB1*1501–DQw6 43–58 peptide complexes, DRB1*1501 molecules,
or MBP 85–99 peptide. Bound MK16 Fab-phages were detected with bi-
otin-labeled rabbit anti–Fd bacteriophage by ELISA. Each symbol repre-
sents a single determination.
Figure 2. Competition biopanning selects for Fab-phages that bind
specifically to the DRB1*1501–MBP 85–99 complex. (A) A pool of
phages from panning rounds 1–5 was isolated, and DRB1*1501–peptide
specificity was assayed by ELISA. Microtiter wells were coated with puri-
fied DRB1*1501 molecules in complex with MBP 85–99 or with DQw6
43–58 peptides, without peptide, or without DR molecules. Bound
phages were detected with biotin-labeled rabbit anti–fd bacteriophage.
Bars illustrate a representative set of data. (B) The amount of immobilized
DRB1*1501–peptide complex was quantitated by biotin-labeled mAb
L243. The mean and SEM (n 5 2) are shown.1401 Krogsgaard et al.
Fine Specificity of MK16. MBP peptide residues re-
quired for recognition by MK16 were examined using a
panel of single amino acid analogues of MBP 85–99 pep-
tide as well as peptides with NH2- or COOH-terminal
truncations. Soluble DRB1*1501 molecules were incu-
bated with monosubstituted Ala analogues and truncated
variants of MBP 85–99 peptide and tested for their ability
to inhibit the binding of MK16 to immobilized DRB1*
1501–MBP 85–99 peptide complexes. Ala substitution of
Phe-92 and Val-96 resulted in a 20–40-fold reduction in
relative binding affinity of MK16, whereas binding was dis-
rupted by Ala substitution of Pro-98 and Arg-99. All other
Ala substitutions only had a very modest effect on the bind-
ing of MK16 (Table I, top section).
We also analyzed the MBP 85–99 peptide binding speci-
ficity of purified DRB1*1501 molecules. Val-89 and Phe-
92 were shown to occupy the hydrophobic P1 and P4
pockets of the DRB1*1501 peptide binding site (Table I,
top section), which is in accordance with previously pub-
lished results (7, 15, 30). Consistent with the peptide bind-
ing requirements for these two pockets, substitution of Val-
89 with the negatively charged Asp greatly diminished the
binding affinity of MK16, and substitution of Phe-92 to
Asp completely abrogated binding (Table I, bottom sec-
Figure 4. In FACS® analysis, MK16 only recognizes MBP 85–99 pep-
tide on cell surfaces when presented by DRB1*1501 molecules. L cell
transfectants expressing either (A) DRB1*1501 molecules or (B)
DRB5*0101 molecules were incubated in the presence of MBP 85–99
peptide, DQw6 43–58 peptide, or no peptide for 2 h and incubated with
purified MK16 or an isotype control, 13.4.1, as indicated (thick lines).
Bound antibody was detected with biotin-labeled goat anti–mouse Ig (Fab
specific), followed by R-PE–conjugated streptavidin. HLA-DR surface
expression was quantified by using biotin-labeled mAb L243 (thick lines).
The thin line and dotted lines represent data obtained by incubating cells
without primary antibody or without a secondary reagent, respectively.
Figure 5. In FACS® analysis, MK16 stains DRB1*1501–MBP pep-
tide complexes when presented by human mononuclear cells. Adherent
mononuclear cells from a DR2-positive donor (DRB1*1501 homozy-
gous) were isolated and incubated with MBP 85–99 peptide (thick
lines), DQw6 43–58 peptide (uneven broken line), or without peptide
for 2 h (thin line), washed twice, and stained with purified MK16 or an
isotype control (Fab 13.4.1). HLA-DR expression was quantified by us-
ing biotin-labeled mAb L243. Bound antibodies were detected as de-
scribed in Fig. 4. Broken lines represent data obtained by incubating
cells without primary antibody.
Figure 6. MK16 recognizes DRB1*1501–MBP peptide complexes
produced by intracellular processing. A HLA-DR2 homozygous B cell
line (MGAR) that expresses DRB1*1501 and DRB5*0101 was incu-
bated with recombinant MBP for 24 h or with MBP 85–99 peptide,
DQw6 43–58 peptide, or without peptide for 2 h. After this incubation,
cells were washed and stained with purified MK16 or an isotype control
(Fab 13.4.1; thick lines). Bound antibodies were detected as described
above. HLA-DR surface expression was quantified by using biotin-
labeled mAb L243 (thick lines). Thin and dotted lines represent data ob-
tained by incubating cells without primary antibody or without the sec-
ondary reagent, respectively.1402 Visualization of MBP T Cell Epitopes in MS Lesions
tion). Substitution of Phe-92 by Tyr (Table I, bottom sec-
tion) did not reduce binding by MK16, consistent with the
preference of the P4 pocket for aromatic side chains. Pep-
tides with NH2- and COOH-terminal truncations delin-
eated the minimal peptide sequence required for MK16
binding. Deletion of Arg-99 abolished MK16 binding,
whereas deletion of the NH2-terminal segment (residues
85–88) had no effect (Table I, center section). Truncation
Table I. Recognition by MK16 Is Affected by Single Amino Substitutions and Truncations of the MBP 85–99 Peptide
Residue no. and position in the binding pocket
85 86 87 88 89 90 91 92 93 94 95 96 97 98 99
P-3 P-2 P-1 P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11
Peptide Alanine analogs
IC50 
MK16
IC50 
DRB1*1501
nM nM
(85–89) E N P V V H F F K N I V T P R 6 5
85 (E®A) A N P V V H F F K N I V T P R 4 7
86 (N®A) E A P V V H F F K N I V T P R 2 7
87 (P®A) E N A V V H F F K N I V T P R 4 10
88 (V®A) E N P A V H F F K N I V T P R 4 10
89 (V®A) E N P V A H F F K N I V T P R 4 50
90 (H®A) E N P V V A F F K N I V T P R 13 10
91 (F®A) E N P V V H A F K N I V T P R 9 10
92 (F®A) E N P V V H F A K N I V T P R 217 199
93 (K®A) E N P V V H F F A N I V T P R 18 4
94 (N®A) E N P V V H F F K A I V T P R 19 4
95 (I®A) E N P V V H F F K N A V T P R 10 4
96 (V®A) E N P V V H F F K N I A T P R 131 4
97 (T®A) E N P V V H F F K N I V A P R 5 4
98 (P®A) E N P V V H F F K N I V T A R .1,000 5
99 (R®A) E N P V V H F F K N I V T P A .1,000 5
NH2- or COOH-terminal truncations
(85–99) – N P V V H F F K N I V T P R 2 3
(87–99) – – P V V H F F K N I V T P R 2 5
(88–99) – – – V V H F F K N I V T P R 4 30
(89–99) – – – – V H F F K N I V T P R 9 253
(90–99) – – – – – H F F K N I V T P R .1,000 .1,000
(91–99) – – – – – – F F K N I V T P R .1,000 .1,000
(85–98) E N P V V H F F K N I V T P – .1,000 4
(85–97) E N P V V H F F K N I V T – – .1,000 15
(85–96) E N P V V H F F K N I V – – – .1,000 20
Single amino acid substitutions
89 (V®D) E N P V D H F F K N I V T P R 214 281
92 (F®Y) E N P V V H F Y K N I V T P R 6 12
92 (F®D) E N P V V H F D K N I V T P R .1,000 .1,000
MK16 Fab-phages were mixed with various concentrations of purified DRB1*1501 molecules loaded with peptides containing the indicated single
amino acid substitutions or truncations, followed by incubation in microtiter wells coated with DRB1*1501–MBP 85–99 peptide complexes. Bound
MK16 Fab-phages were detected with biotin-labeled rabbit anti–Fd bacteriophage by ELISA. For peptide binding and specificity of purified
DRB1*1501 molecules isolated from S2/DRB1*1501 cells, a constant amount of DRB1*1501 molecules was incubated in the presence of a fixed
concentration of biotin-labeled MBP 85–99 peptide and increasing amounts of competitor peptide. The concentration of competitor complex needed
to result in IC50 was determined. Binding values for residues critical for binding are in bold type. Each peptide was analyzed in three independent
experiments, and results are represented as mean values.1403 Krogsgaard et al.
of Val-89 disrupted binding of MK16, as this residue repre-
sents a primary anchor for the binding of the MBP 85–99
peptide to DRB1*1501 (Table I, center section; reference
7, 15, 30). These results demonstrated that the two major
HLA-DR2 anchor residues of MBP 85–99 peptide were
required for MK16 binding and that the COOH-terminal
part of the peptide, in particular residues Val-96, Pro-98,
and Arg-99, contributed to binding. Taken together, these
data strongly suggest that MK16 binds directly over the
HLA–peptide complex.
MK16 Binds with a Lower Affinity than Two Pan-reactive
Anti-DR Antibodies. The specificity of MK16 was further
examined in a competition binding assay with two pan-
reactive anti-HLA-DR antibodies, mAb L243 and mAb
L227 (31, 32), that are both capable of blocking DR-
restricted T cell responses. mAb L243 recognizes a mono-
morphic determinant on the outer loops of the DR a
chain (33), and mAb L227 recognizes a determinant of the
DR b chain (31, 32). In this experiment, purified mAb
L243, mAb L227, and soluble MK16 was used to inhibit
the binding of MK16 Fab-phages to immobilized DRB1*
1501–MBP 85–99 peptide complexes. The anti-DR anti-
bodies L243, L227, and soluble MK16 Fab blocked binding
of MK16 Fab-phages in a dose-dependent manner (Fig. 7),
whereas an isotype control Fab (13.4.1) did not inhibit
binding. The experimentally determined IC50 values were
21 nM for MK16 and 0.8 nM for both mAb L227 and
mAb L243. These results demonstrated that MK16 had an
z30-fold lower affinity than the two anti-DR antibodies
and that the binding site of MK16 appeared to overlap with
the determinants recognized by mAb L243 and mAb L227.
MK16 Can Block the MBP-specific Stimulation of HLA-
DR2–restricted T Cells. We next compared the ability of
mAb L243 and MK16 to inhibit the MBP 85–99 peptide–
specific stimulation of two DRB1*1501-restricted TCR
transfectants (Hy.2E11 and Ob.1A12) that were generated
with TCR sequences from human MBP–specific T cell
clones (7, 20). MK16 was able to block both T cell hybrid-
omas, although to a different extent. The maximal IL-2
response of Hy.2E11 could be inhibited by .90%, whereas
Ob.1A12 could be inhibited only by z50% (Fig. 8). mAb
L243 could inhibit the maximal IL-2 response of both T
cell hybridomas by .90%. The inhibition by MK16 and
L243 antibodies was specific, because neither of the T cells
was affected by the addition of an isotype control (Fab
13.4.1; data not shown).
We next compared the IC50 values for inhibiting the
Hy.2E11 and Ob.1A12 T cells with MK16 and L243 anti-
bodies (Fig. 8). Dose–response experiments demonstrated
that a 50-fold higher concentration of MK16 was needed
to inhibit Ob.1A12 to the same degree as Hy.2E11. Fur-
thermore, a sevenfold higher concentration of MK16 was
needed to reach a degree of inhibition of Hy.E211 similar
to that obtained with mAb L243. This was even more
pronounced when Ob.1A12 was investigated, as a 100-
fold higher concentration of MK16 as compared with
mAb L243 was needed to block the antigen-specific IL-2
response of this T cell hybridoma. Inhibition of DRB1*
1501-restricted T cells was specific, as MK16 blocked nei-
ther the antigen-specific stimulation of two DRB1*1501-
restricted T cell hybridomas recognizing two different PLP
peptides (PLP 40–60 and PLP 95–116) nor two DRB1*
0401-restricted T cell hybridomas recognizing two differ-
ent peptides (CII 261–273 and HA 307–319), which were
readily inhibited by mAb L243 (Fig. 8).
MK16 Has a Sensitivity Similar to That of T Cells Specific
for the HLA-DR2–MBP Peptide Complex. We next in-
vestigated whether MK16 could detect DRB1*1501–
MBP 85–99 peptide complexes with the same sensitivity
as the two TCR transfectants, Hy.2E11 and Ob.1A12. In
this experiment, MGAR cells were first cultured in the
presence of various concentrations of recombinant MBP,
MBP 85–99, or DQw6 43–58 peptides. These APCs were
then stained with MK16 (Fig. 9, A and C) or cultured
with Hy.2E11 (Fig. 9 B) or Ob.1A12 TCR transfectants
(data not shown). The minimal antigen–peptide concen-
tration required for significant staining with MK16 was
1–2 nM, whereas a concentration of 10–100 nM peptide
was required to elicit a specific IL-2/T cell response. The
original human T cell clones from which the TCR chains
were isolated were more sensitive than the TCR transfec-
tants and were activated by MBP 85–99 peptide at 5 nM
(data not shown). These results demonstrated that MK16
detected complexes of DRB1*1501 and MBP 85–99 pep-
tide with a sensitivity similar to that of human T cell
clones.
Intracellular Localization of HLA-DR2–MBP Peptide Com-
plexes. We also examined whether MK16 could be used
to label intracellular DRB1*1501–MBP peptide com-
plexes at a single cell level by using laser scanning confocal
microscopy. Immunostaining of DRB1*1501-positive L
cells preincubated with either recombinant MBP or the
MBP 85–99 peptide showed intracellular staining that was
confined to vesicular structures in the cytoplasm.  The
staining pattern was similar when the transfectants were
Figure 7. MK16 binds with a lower affinity than two monomorphic
anti–HLA-DR mAbs, L243 and L227. Microtiter wells coated with
DRB1*1501–MBP 85–99 peptide complexes were incubated with a
fixed concentration of MK16 Fab-phages and various concentrations of
the following competing antibodies: mAb L243, mAb L227, soluble
MK16 Fab, or isotype control 13.4.1. Bound MK16 Fab-phages were de-
tected with biotin-labeled rabbit anti–fd bacteriophage by ELISA. The
mean and SEM (n 5 2) are shown.1404 Visualization of MBP T Cell Epitopes in MS Lesions
pulsed with either recombinant MBP or the MBP 85–99
peptide. DRB1*1501-positive L cells that had not been
incubated with MBP or had been incubated with the
DQw6 43–58 peptide were not stained by MK16 (Fig.
10). Staining was also negative with an isotype control an-
tibody (13.4.1) or in the absence of the primary antibody
(data not shown). DRB1*1501-positive L cells incubated
with an anti-CD107a mAb that recognizes LAMP-1
showed a similar vesicular staining pattern. Double stain-
ing with anti-CD107a and MK16 showed a certain degree
of colocalization of these molecules. However, a substan-
tial fraction of MK16-positive vesicles was not stained by
the LAMP-1 antibody, suggesting that MK16 also labels
DRB1*1501–MBP peptide complexes in other vesicles of
the endosomal/lysosomal pathway. These results demon-
strated that MK16 could be used to specifically label
Figure 8. MK16 can inhibit
DRB1*1501-restricted MBP-spe-
cific T cell hybridoma response to
MBP–peptide. MGAR cells (ex-
pressing DRB1*1501 and DRB5*
0101 molecules) were cultured
with MBP 85–99, PLP 95–116, or
PLP 40–60 peptides for 2 h or re-
combinant MBP for 24 h. Priess
cells (expressing DRB1*0401 mol-
ecules) were cultured in the pres-
ence of CII 261–273 or HA 307–
319 peptides for 2 h. Cells were
washed, irradiated with 3,000 rads,
and incubated in the presence of
increasing concentrations of block-
ing antibodies for 30 min at 378C
before adding the T cell hybrid-
omas. After incubation for 24 h, ali-
quots of 100 ml were assayed in an
IL-2 release assay. The mean and
SEM (n 5 2) are shown. Antibody
concentrations needed to effect
50% inhibition (IC50) of secreted
IL-2 by Hy.2E11 or Ob.1A12 hy-
bridomas when using MK16 as in-
hibitor were 22 and 1,000 nM, re-
spectively, and when using mAb
L243 as inhibitor were 3 and 10
nM, respectively. MK16 did not
inhibit presentation of PLP 40–60
and PLP 95–116 peptides to DRB1*
1501-restricted 5C6 and 106J T
cell hybridomas nor of CII 261–
273 or HA 307–319 peptides to
DRB1*0401-restricted CII 3838
and HA 3.3 T cell hybridomas,
whereas IC50 values, when using
mAb L243 as inhibitor of IL-2 se-
cretion by these hybridomas, were
26, 22, 0.08, and 0.06 nM, respec-
tively.1405 Krogsgaard et al.
DRB1*1501–MBP peptide complexes at a single cell
level.
Immunoreactivity of Sections of MS and Normal Brain Tissue.
To directly examine the identity of the cells that pre-
sented the DRB1*1501-bound MBP 85–99 peptide in MS
lesions, we used MK16 for immunohistochemical staining
of MS brain tissue. Normal brain tissue was also analyzed.
Frozen sections of CNS tissue from 11 MS cases with
chronic active lesions (Table II) and from 7 normal cases
(data not shown) were HLA typed. Eight patients were
DRB1*1501 positive and one was DRB1*1502 positive,
while two were DRB1*1501 and DRB1*1502 negative.
One of seven normal cases was DRB1*1501 positive. Sec-
tions from all patients and the DRB1*1501-positive case
were stained with a pan-reactive anti–HLA class II mAb
(anti–HLA-DP-DQ-DR) and MK16, as well as with anti-
bodies to microglia/macrophages, monocytes, and astro-
cytes. In sections from all MS patients, the pan-reactive
anti–HLA class II antibody reacted strongly with micro-
glia/macrophages (as exemplified in Fig. 11 B and Fig. 12,
A and C). In the majority of MS cases examined, regardless
of HLA type, the same pan-reactive antibody also showed a
low level of immunoreactivity of astrocytes within lesion
areas and of occasional monocytes but no reactivity with
blood vessel endothelium. In the DRB1*1501-positive
normal case, the pan-reactive anti–HLA class II antibody
stained only microglia/macrophages in the white matter
but with greatly reduced intensity compared with MS le-
sions (data not shown).
When MK16 was applied to the same tissues, a clear dif-
ference in immunoreactivity between sections from DR2-
positive patients and HLA-DR2–negative patients was seen
(Table II and Fig. 11, A and D). On sections from HLA-
DR2–positive patients, MK16 stained predominantly cells
that on the basis of their morphology were characterized as
microglia/macrophages (Fig. 11 A). The intensity of this
staining and the number of stained cells were lower as
compared with the pan-reactive anti–HLA class II antibody
(Fig. 11, A and B). In contrast, microglia, macrophages, as-
trocytes, and monocytes from the HLA-DR2–negative pa-
tients were all MK16 negative, while the occasional blood
vessel exhibited very low level MK16 reactivity (Table II,
patient no. M46 and F56; exemplified in Fig. 11 D). In the
normal DRB1*1501-positive case, MK16 also labeled mi-
croglia/macrophages but not astrocytes. As compared with
the staining pattern in MS lesions, fewer cells were MK16
positive, and their reactivity was weaker (Fig. 11 C). A
higher level of background staining was observed in the
normal DRB1*1501-positive case than in the HLA-DR2–
positive patients, because the specimen of normal CNS had
to be developed for a longer period to visualize staining.
Double immunofluorescence staining of the DR2-posi-
tive MS lesions directly demonstrated that although the
MK16-positive cells also were HLA class II positive (Fig.
12, A–C), some HLA class II–positive cells were MK16
negative (Fig. 12 C, lower right corner). Double staining
also showed that MK16-positive cells were CD14 positive
(as exemplified in Fig. 12, D–F), confirming that these cells
were microglia/macrophages. White matter from three of
the DR2-positive patients also showed immunoreactivity
for MK16 on hypertrophic astrocytes (Table II, patient nos.
F31, F38, and F55; exemplified in Fig. 12, G–I), whereas
one patient showed reactivity only on astrocytes (Table II,
patient no. F36). In addition, lesions from two patients
showed monocytes to be positive for the MK16 antibody
(Table II, patient nos. F37 and M69). It was important to
Figure 9. MK16 detects DRB1*1501–MBP 85–
99 peptide complexes with a sensitivity similar to
that of DRB1*1501-restricted MBP-specific T cell
hybridoma. MGAR cells (expressing DRB1*1501
and DRB5*0101) were cultured with various con-
centrations of MBP 85–99 peptide, DQw6 43–58
peptide, or recombinant MBP for 2 or 24 h, respec-
tively. (A) After this incubation, cells were stained
with purified MK16 followed by incubation with bi-
otin-labeled goat anti–mouse Ig (Fab specific) and
detected with R-PE–labeled streptavidin. (B) T cell
stimulation. In parallel, pulsed and irradiated cells
were cocultured with T cell hybridomas Hy.2E11 or
Ob.1A12 for 24 h (only data for Hy.2E11 are
shown; similar results were obtained for Ob.1A12).
Aliquots of 100 ml were assayed in an IL-2 release as-
say. Each symbol represents the mean value of two
determinations. (C) Summary of experiments per-
formed in A and B. Curves illustrate the amount of
binding presented as mean values measured by flow
cytometry analysis. The mean and SEM (n 5 2) are
shown. The box labeled T cells represents the range
of minimal peptide concentration needed for elicit-
ing detectable IL-2 responses determined by three
individual experiments.1406 Visualization of MBP T Cell Epitopes in MS Lesions
show that potentially autoreactive T cells are found adja-
cent to MK16-positive APCs in the MS lesions. Double
staining with anti-CD3 and MK16 demonstrated that this
was indeed the case (as exemplified in Fig. 12, J–L). Taken
together, these results demonstrated that MK16 could be
used to localize APCs in MS lesions and normal brain tissue
that present the DRB1*1501–MBP peptide complex and
that these cells were predominantly microglia/macrophages.
However, the frequency and staining level of MK16-posi-
tive cells was markedly higher in the MS lesions than in
normal brain tissue, and T cells adjacent to these APCs
were only observed in the MS lesions.
Discussion
Antibodies against specific MHC–peptide complexes are
relatively new tools that have already proven to be valuable
in the study of antigen processing and presentation. Using
such antibodies, it has been possible to localize, quantitate,
and detect specific MHC–peptide complexes in situ (25,
29, 34–47). Previously reported antibodies directed against
MHC class II–bound peptides were derived from either
endogenous proteins such as invariant chain and a mouse
MHC class II molecule (I-Ea) or exogenous model anti-
gens (e.g., hen egg lysozyme). Conventional hybridoma
technology has been used in combination with optimized
Figure 10. Colocalization of DRB1*1501–MBP peptide complexes and LAMP-1. L cells expressing DRB1*1501 molecules were cultured with or
without the presence of MBP 85–99 peptide or DQw6 43–58 peptide for 2 h or with recombinant MBP for 24 h. Cells were washed, fixed, permeabi-
lized, and incubated with purified MK16 and a rat anti–LAMP-1 antibody. MK16 and LAMP-1 were visualized by FITC-labeled goat anti–mouse IgG
(Fab specific) antibody (green) and Texas Red–labeled goat anti–rat IgG (Fc fragment specific) antibody (red), respectively. Colocalization is visualized in
yellow. The images are one optical section thick. Original magnification, 340.1407 Krogsgaard et al.
immunization and screening strategies to generate such an-
tibodies. In these studies, it was reported that comprehen-
sive and rigorous screening of a large number of hybridoma
clones (500–1,000) resulted in the recovery of only 1–2
clones with the desired specificity (for example, see refer-
ences 41 and 42). These numbers indicate that antibodies
with such specificities tend to be relatively rare and difficult
to isolate.
We chose to generate an antibody that specifically rec-
ognized a human MHC class II molecule, DRB1*1501, in
complex with an autoantigenic peptide (MBP 85–99). We
used the phage display technique because we have previ-
ously shown that this technique represents an attractive al-
ternative to hybridoma technology to generate an antibody
against a defined MHC class I–peptide complex (24). The
HLA-DRB1*1501–MBP complex was selected because it
is a target for autoreactive T cells in MS (6, 7, 11, 12, 48;
for review see reference 3) and because the structural re-
quirements for binding of the MBP 85–99 peptide to
DRB1*1501 molecules and for its recognition by cognate
TCR have been analyzed in great detail. Peptide binding
studies and structure determination by x-ray crystallogra-
phy demonstrated that Val-89 and Phe-92 are major an-
chor residues that are accommodated in the hydrophobic
P1 and P4 pockets of the DRB1*1501 molecule (7, 15,
30). In accordance with these results, we have shown that
MK16 is sensitive to amino acid changes at these positions.
The epitope recognized by the antibody is located at the
COOH-terminal end of the MBP 85–99 peptide and in-
volves residues Val-96, Pro-98, and Arg-99. In contrast,
residues His-90, Phe-91, and Lys-93 are particularly im-
Table II. MK16 Reactivity with CNS Tissue from 11 Different 
MS Cases
DR2 positive
Patient 
no.
DRB1 
alleles
Microglia/
macrophage Astrocytes Other
F31 01, 1501 11 blood vessels
F37 03, 1501 1/2 monocytes
F32 1501, 1601 1/2
F38 03, 1501 111 1/2
F55 1501 11 /2
F36 08, 1501 11
F27 1501 11
F56 1501 1
M69 11, 1502 1/2 monocytes
DR2 negative
M46 03, 13 blood vessels
F56 11, 13 blood vessels
Frozen sections of CNS tissue from 11 MS cases were HLA typed and,
after fixation, stained with the following antibodies: anti–HLA-DR-
DP-DQ or MK16 and anti-CD14 (microglia of the monocyte lineage,
monocytes and macrophages) or CD68 (microglia and macrophages) or
anti-GFAP (astrocytes) antibodies. Slides were scored in a blinded fashion
by two observers on a scale from 0 to 4 based on the degree of positivity.
Figure 11. Immunohistochemical
anti–HLA class II antibody and MK16
stainings of frozen sections from
chronic active MS lesions and normal
CNS tissue. (A) MK16 immunoreac-
tivity at the edge of an active lesion
from a DRB1*1501-positive MS pa-
tient shows staining of four microglial
cells and some astroglial cell processes.
3600. (B) Anti–HLA-DP-DQ-DR
antibody staining of the same MS le-
sion (adjacent section) showing more
intense staining of microglia/mac-
rophages. 3600. (C) DRB1*1501-
matched normal CNS tissue immu-
noreacted with MK16 shows scattered
MK16-positive microglia/macrophages
with lower level immunoreactivity
compared with that seen in MS. A
higher level of background staining
was observed in normal CNS than in
MS lesions, because the specimen of
normal CNS had to be developed for
a longer period to visualize staining.
3600. (D) Non–HLA-matched chronic
active MS lesion immunoreacted with
MK16. A rare blood vessel shows pos-
itive immunoreactivity. Microglia/
macrophages, astrocytes, and mono-
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Figure 12. Double immunofluorescence of frozen sections of white matter from a DRB1*1501-positive patient with chronic progressive MS. Panels A–C are
stained by using an anti–HLA class II antibody and MK16. (A) The section was immunoreacted with the anti–HLA-DP-DQ-DR antibody and visualized with
an Alexa 568–conjugated secondary antibody (red). An area from an acute lesion displays immunoreactivity on numerous macrophages and microglia around a
blood vessel (upper right). A few hypertrophic astrocytes are also immunoreactive (bottom center and left). 3500. (B) The same field reacted with MK16 and vi-
sualized with a Cy-2–conjugated secondary antibody (green). Note the immunoreactive microglial cells around the blood vessel. Not all HLA class II–positive
cells are MK16 positive. 3500. (C) Double immunofluorescence of the same field shows overlapping HLA class II/MK16 reactivity (yellow/orange) on the ma-
jority of cells, while some cells are HLA class II positive only (red). Two perivascular microglial cells are predominantly MK16 positive. 3500. Panels D–F are
stained by using an anti-CD14 antibody and MK16. (D) A row of perivascular macrophages in the same acute lesion (adjacent section) immunoreacted with anti-
CD14 mAb and visualized with Alexa 568 (red). 3500. (E) The same macrophages are MK16 positive, which can be visualized with the Cy-2–labeled secondary
antibody (green). The surrounding tissue have a high green autofluorescence, which is partly the result of our enhancement of the image to maximize the staining
of MK16-positive cells (this is also the case in H, K, I, and L) and partly due to the quality of postmortem inflamed tissue. 3500. (F) Double immunofluorescence
shows clear overlap between CD14 and MK16 on the same macrophages. 3500. Panels G–I are stained by using an anti-GFAP antibody and MK16. (G) A hy-
pertrophic astrocyte (red; Alexa 568) and numerous astroglial cell processes are immunoreactive for GFAP. 3500. (H) With MK16, the same hypertrophic astro-
cyte and its processes are Cy-2 positive (green). 3500. (I) Double immunofluorescence shows clear overlap (yellow/orange) between anti-GFAP and MK16.
3500. Panels J–L are stained by using an anti-CD3 antibody and MK16. Because this image is of a perivascular cuff, the plane of focus is different both between
cells and from the surrounding parenchyma and therefore appears fuzzy. (J) A perivascular cuff of infiltrating cells from the same acute lesion as above shows dif-
fuse immunoreactivity for anti-CD3 (red; Alexa 568). 3500. (K) The same perivascular infiltrate shows a different pattern of immunoreactivity with MK16
(green; Cy-2). 3500. (L) Double immunofluorescence shows distinct staining of CD3- and MK16-positive cells within the same perivascular cuff. 3500.1409 Krogsgaard et al.
portant for recognition by human MBP–specific T cell
clones (7, 49). MK16 could also inhibit recognition of
MBP 85–99 peptide by the two T cell hybridomas
(Ob.1A12 and Hy.2E11), although to a different extent.
Although Hy.2E11 could be blocked .90%, Ob.1A12
could only be blocked to z50% of the maximal response.
Even though mAb L243 efficiently inhibited both T cell
hybridomas, we showed that MK16 had a .30-fold lower
affinity than mAb L243. Subtle differences in the position-
ing of the two TCRs on the HLA-DR2–MBP peptide
complex may contribute to the different degree of blocking
with MK16. His-90 and Phe-91 represent primary TCR
contact residues for clone Ob.1A12, whereas Phe-91 and
Lys-93 are primary TCR contact residues for clone
Hy.2E11 (7, 49).
An mAb recognizing an MS-relevant T cell epitope may
have therapeutic potential. An mAb specific for an I-As–
MBP complex was found to block the proliferative T cell
response in vitro to the I-As–restricted encephalitogenic
determinant of MBP and to inhibit experimental allergic
encephalomyelitis (EAE) in H-2s mice (50). By analogy,
we are currently testing whether MK16 can inhibit EAE in
a newly developed humanized animal model for MS (20).
If this is the case, MK16 might have clinical relevance in
the treatment of MS. Alternatively, MK16 antibody could
be expressed as an intact antibody with an Fc segment that
fixes complement. Such a strategy would target APCs that
phagocytose myelin and present myelin-derived peptides to
T cells but would spare oligodendrocytes that do not ex-
press MHC class II molecules (51). Antibodies to human
MHC class II molecules (DR7 and DRw11) in complex
with MBP fragments have also been reported (52) but may
not be suitable for clinical purposes. DR7 and DRw11 are
not associated with susceptibility to MS; the antibodies
showed significant background reactivity with endogenous
MHC–peptide complexes, and the precise MBP epitopes
recognized by these antibodies were not defined.
MK16 represents a powerful tool to investigate MHC
class II presentation of MBP and may contribute to our un-
derstanding of molecular mechanisms involved in the de-
velopment of MS. Recent studies have provided evidence
that HLA-DR–restricted presentation of MBP by trans-
formed B cells and fibroblast transfectants can occur via
two different alternative pathways, which are both inde-
pendent of intracellular processing involving the lysosomes
(53, 54). We have shown in this study that the MK16 anti-
body could be used to detect HLA-DR2–MBP peptide
complexes at the single cell level. Importantly, the anti-
body-stained APCs pulsed with intact MBP and could de-
tect intracellular complexes, which colocalized with lyso-
somes, indicating that MBP is also processed in the
endosomal/lysosomal pathway like the vast majority of
other exogenous antigens.
MK16 was also used to visualize cells that present MBP
T cell epitopes in MS lesions, a topic of interest because it
is unclear which cells in the CNS might serve as APCs and
stimulate myelin-reactive infiltrating CD41 T cells. In par-
ticular, there is some controversy as to the relative role of
microglia/macrophages and astrocytes as APCs. Phenotypic
analysis of human brain tissue has shown that MHC class II
molecules are readily detectable on microglia/macro-
phages, whereas astrocytes have much lower, if any, MHC
class II expression (55). In MS, both microglia/macro-
phages and astrocytes become activated and express higher
levels of MHC class II molecules (55–57). In addition, mi-
croglia/macrophages but apparently not astrocytes express
costimulatory molecules such CD80 and CD40 that are
critical for T cell activation (58, 59). These findings suggest
that microglia/macrophages rather than astrocytes are the
predominant APCs in MS lesions. However, functional
studies in vitro have questioned this relatively simple para-
digm and given evidence that both activated microglia/
macrophages and activated astrocytes may act as efficient
APCs and stimulate naive as well as activated T cells (for
recent publications see references 60–63). It should be
noted that the majority of these studies have been carried
out in rodents and might therefore not be directly relevant,
as microglia/macrophages and astrocytes show important
interspecies phenotypic differences, such as inducibility of
CD80 expression (for review see references 16–18). Our
results demonstrated unequivocally that microglia/mac-
rophages were the cell type most consistently staining posi-
tively with MK16 in HLA-DR2 (DRB1*1501 and 1502)-
positive MS patients. Importantly, a few lesions also
showed reactivity on hypertrophic astrocytes and mono-
cytes within lesion areas. The level of MK16 reactivity was
less intense than that observed with a pan-reactive anti–
HLA-DP-DQ-DR antibody. This difference might have
been expected, because MK16 only recognizes a subset of
HLA-DR molecules, i.e., those binding the MBP 85–99
peptide, which is in contrast to the anti–HLA-DP-DQ-
DR antibody, which recognizes all HLA class II molecules.
It is interesting that microglia/macrophages reacting
with the pan-reactive anti–HLA class II antibody did not
always also stain with MK16. This dichotomy may suggest
that not all microglia/macrophages have the capacity to
process MBP and might reflect the presence of microglia/
macrophage cells at different developmental stages or ex-
hibiting differential activation. Alternatively, this result may
indicate that microglia/macrophages are a heterogeneous
population of cells, some of which are long-term residents
of the CNS and some of which may be of recent hematog-
enous derivation in which only a fraction has the ability to
process MBP and other antigens. The differential staining
of some microglia/macrophages with the pan-reactive anti-
HLA class II antibody and MK16 also shows that MK16
staining is not, in general, merely a function of cross-reac-
tivity with DRB1*1501 molecules bound to other self-
peptides. If this had been the case, we would have expected
MK16 to react with all DRB1*1501-positive cells. This
conclusion is further substantiated by the findings that
MK16 only stained adherent mononuclear cells from a
DRB1*1501-positive donor and DRB1*1501-positive L
cell transfectants and a DRB1*1501-positive B cell line
(MGAR) when these different cell types had been incu-
bated with the MBP 85–99 peptide.
Our studies do not resolve whether microglia/macro-
phages or astrocytes presenting the HLA-DRB1*1501–MBP1410 Visualization of MBP T Cell Epitopes in MS Lesions
complex have the capacity to stimulate T cells but merely
show that they both have the potential. Importantly, the
observation also strongly suggests that both cell types can
process native MBP, though it cannot be excluded that the
HLA-DRB1*1501–bound MBP 85–99 peptide is derived
from extracellular degradation of MBP (64, 65). Moreover,
our studies do not emphasize the role of the DRB1*1501
molecule at the expense of the DRB5*0101 and DQB1*
0602 molecules as the principal MS-associated MHC class
II gene in the DR2 haplotype. Population studies in differ-
ent ethnic groups might be the best way to examine which
of these three MS-associated class II genes confer the stron-
gest susceptibility to MS. It is also important to note that
other MHC class II molecules than those encoded in the
DR2 haplotype and CNS-derived antigens other than my-
elin are also likely to play an important role in the patho-
genesis of MS.
Our data also show that the HLA-DRB1*1501–MBP
complex is presented by microglia/macrophages in normal
brain, albeit at a lower level and by fewer cells than in the
MS lesions. So far, this analysis has only been done on a
single postmortem case, as only one of the seven control
subjects carried the HLA-DR2 haplotype. These observa-
tions indicate that low level DR-restricted MBP presenta-
tion in the brain is normal rather than pathologic. These
results also support the notion that T cell entry into CNS
might be a critical checkpoint in the initiation of disease,
because physiologic expression of MHC class II–MBP
complexes in the CNS may be sufficient to activate infil-
trating autoreactive T cells (66).
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